摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

{2-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}(phenyl)methanone | 651054-45-4

中文名称
——
中文别名
——
英文名称
{2-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}(phenyl)methanone
英文别名
{2-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl}(phenyl)methanone;[2-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-phenylmethanone
{2-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}(phenyl)methanone化学式
CAS
651054-45-4
化学式
C24H19NO4
mdl
——
分子量
385.419
InChiKey
IKWYJDFTNMSTAW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    57.6
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为产物:
    参考文献:
    名称:
    Synthesis and structure–activity relationship for new series of 4-Phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase
    摘要:
    We discovered a new series of 4-phenoxyquinoline derivatives as potent and selective inhibitors of the platelet-derived growth factor receptor (PDGFr) tyrosine kinase. We researched the highly potent and selective inhibitors on the basis of both PDGFr and epidermal growth factor receptor (EGFr) inhibitory activity. First, we found a compound, Ki6783 (1), which inhibited PDGFr autophosphorylation at 0.13 muM, but it did not inhibit EGFr autophosphorylation at 100 muM. After extensive explorations, we found the two desired compounds, Ki6896 (2) and Ki6945 (3), which are substituted by benzoyl and benzamide at the 4-position of the phenoxy group on 4-phenoxyquinoline, respectively. These inhibitory activities were 0.31 and 0.050 muM, respectively, but neither of them inhibited EGFr autophosphorylation at 100 M. We further investigated the profile of both compounds toward various tyrosine and serine/threonine kinases. The three compounds specifically inhibited PDGFr rather than the other kinases. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2003.08.020
点击查看最新优质反应信息

文献信息

  • Synthesis and Evaluation of [2-(4-Quinolyloxy)phenyl]methanone Derivatives: Novel Selective Inhibitors of Transforming Growth Factor-β Kinase
    作者:Toshiyuki Shimizu、Kaname Kimura、Teruyuki Sakai、Kazuki Kawakami、Tetsuko Miyazaki、Masayoshi Nakouji、Akira Ogawa、Hitomi Ohuchi、Kiyoshi Shimizu
    DOI:10.1021/jm701626z
    日期:2008.6.1
    synthesized and evaluated various [2-(4-quinolyloxy)phenyl]methanone derivatives. These compounds had novel chemical structures that were distinct from those of previously reported inhibitors. Biological data suggested that these compounds inhibited transforming growth factor-beta signaling by interacting with the ATP-binding pocket of the transforming growth factor-beta type I receptor kinase domain. Here,
    我们合成并评估了各种[2-(4-喹啉基氧基)苯基]甲酮衍生物。这些化合物具有不同于先前报道的抑制剂的新颖化学结构。生物学数据表明,这些化合物通过与I型转化生长因子受体激酶结构域的ATP结合口袋相互作用而抑制了TGF-β信号转导。在这里,我们报告了该系列化合物的合成与构效关系。
  • Compound having tgfß inhibitory activity and medicinal composition containing the same
    申请人:Shimizu Kiyoshi
    公开号:US20060111375A1
    公开(公告)日:2006-05-25
    The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.
    本发明提供了以下公式(I)所表示的化合物及其药学上可接受的盐和溶剂: 其中,X代表CH或N;Z代表-O-,-NH-或-C(=O)-;R和R'代表氢原子,羟基,卤原子,可选择取代的烷基,可选择取代的烯基,可选择取代的烷氧基,氨基,氨基甲酰基或可选择取代的杂环基;A代表可选择取代的特定环烷基或杂环基。本发明的化合物具有出色的TGFβ抑制活性。
  • COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    申请人:Shimizu Kiyoshi
    公开号:US20090312313A1
    公开(公告)日:2009-12-17
    The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.
    本发明提供了由式(I)表示的化合物及其药学上可接受的盐和溶剂: 其中,X代表CH或N;Z代表—O—、—NH—或—C(═O)—;R和R′代表氢原子、羟基、卤素原子、可选取代的烷基、可选取代的烯基、可选取代的烷氧基、氨基、氨基甲酰基或可选取代的杂环基;A代表可选取代的特定环烷基或杂环基。本发明的化合物具有优异的TGFβ抑制活性。
  • Compound having TGFβ inhibitory activity and medicinal composition containing the same
    申请人:Kirin Beer Kabushiki Kaisha
    公开号:US07560558B2
    公开(公告)日:2009-07-14
    The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.
    本发明提供了由式(I)表示的化合物及其药学上可接受的盐和溶剂化物:其中,X代表CH或N;Z代表—O—,—NH—或—C(═O)—;R和R'代表氢原子、羟基、卤素原子、可选取代的烷基、可选取代的烯基、可选取代的烷氧基、氨基、氨基甲酰基或可选取代的杂环基;A代表可选取代的特定碳环或杂环基。根据本发明的化合物具有优异的TGFβ抑制活性。
  • COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
    申请人:KIRIN BEER KABUSHIKI KAISHA
    公开号:EP1548008A1
    公开(公告)日:2005-06-29
    The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents -O-, -NH- or - C(=O)-; R and R' represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.
    本发明提供了式 (I) 所代表的化合物及其药学上可接受的盐和溶剂: 其中 X 代表 CH 或 N;Z 代表 -O-、-NH- 或 -C(=O)-;R 和 R' 代表氢原子、羟基、卤素原子、任选取代的烷基、任选取代的烯基、任选取代的烷氧基、氨基、氨基羰基或任选取代的杂环基团;A 代表任选取代的特定碳环或杂环基团。本发明的化合物具有优异的 TGFβ 抑制活性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐